Last $2.19 USD
Change Today +0.04 / 1.86%
Volume 27.7K
As of 8:10 PM 05/22/13 All times are local (Market data is delayed by at least 15 minutes).

verenium corp (VRNM) Snapshot

Open
$2.18
Previous Close
$2.15
Day High
$2.25
Day Low
$2.13
52 Week High
07/26/12 - $4.69
52 Week Low
11/16/12 - $2.05
Market Cap
28.0M
Average Volume 10 Days
29.1K
EPS TTM
$-1.31
Shares Outstanding
12.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERENIUM CORP (VRNM)

Related News

No related news articles were found.

verenium corp (VRNM) Related Businessweek News

View More BusinessWeek News

verenium corp (VRNM) Details

Verenium Corporation, an industrial biotechnology company, engages in the development and commercialization of enzymes for industrial processes in North America, Europe, South America, and Asia. The company manufactures and markets its proprietary enzyme products in the fields of animal health and nutrition, grain processing, oilfield services, and other industrial processes, such as pulp and paper, and textiles. Its animal health and nutrition product is Phyzyme XP phytase, an enzyme added to poultry and swine feed that promotes growth by enhancing the nutrition that animals extract from feed grains. The company’s grain processing products comprise Fuelzyme alpha-amylase, an enzyme for starch liquefaction in the production of fuel ethanol and other industrial-use alcohols; DELTAZYM GA L-E5, a high-activity glucoamylase for the conversion of starch to sugars in fuel ethanol production; and Xylathin xylanase, an enzyme that enhances the efficiency of fuel ethanol production from cereal grains. Its oilfield services products include Pyrolase cellulase and Pyrolase HT cellulase, which are enzymes that break carbohydrates in the fluids used in oil and gas well operations; and Eradicake alpha-amylase enzyme, which breaks down starch. The company’s other industrial processes products comprise Cottonase pectate lyase, a textile processing enzyme for cotton; and Luminase PB-100 xylanase, which enhances the reactivity of pulp fiber to bleaching chemicals. It also has enzyme product candidates in various stages of development for animal health and nutrition, grain and starch processing, and oilfield services markets. In addition, the company provides contract manufacturing services. Verenium Corporation has a strategic collaboration with Novus International, Inc. The company was formerly known as Diversa Corporation and changed its name to Verenium Corporation in June 2007. Verenium Corporation was founded in 1992 and is headquartered in San Diego, California.

111 Employees
Last Reported Date: 04/1/13
Founded in 1992

verenium corp (VRNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $677.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Operating Officer, Executive Vice Presi...
Total Annual Compensation: $438.8K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $365.7K
Consultant
Total Annual Compensation: $204.6K
Compensation as of Fiscal Year 2012.

verenium corp (VRNM) Key Developments

Verenium Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013; Provides Earnings Guidance for the Year 2013

Verenium Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company has posted total revenues decreased 20% to $13.8 million from $17.2 million in the prior year, primarily due to license revenue recorded in 2012 from DSM and Novus International. Loss from operations was $3.8 million compared to income from operations of $32.0 million for the prior year, on a GAAP accounting basis, including the impact of the $31.3 million gain on sale of the oilseed processing business to DSM in 2012. Adjusted LBITDA was $2.5 million, compared to Adjusted EBITDA income of $1.4 million for the same quarter in the prior year. The change in Adjusted EBITDA is primarily attributed to license revenue recorded in 2012 from DSM and Novus International, and increased research and development expenses. Net loss from continuing operations was $6.05 million against net income from continuing operations of $29.31 million a year ago. Net loss attributed to Verenium was $6.05 million or $0.47 diluted per share against net income of $29,301,000 or $2.32 diluted per share a year ago. For the year 2013, the company expects adjusted LBITDA to be in between $10 million to $12 million and capital expenditures to be in between $3 million to $4 million.

Verenium Corporation, Q1 2013 Earnings Call, May 09, 2013

Verenium Corporation, Q1 2013 Earnings Call, May 09, 2013

Verenium Corporation to Report Q1, 2013 Results on May 09, 2013

Verenium Corporation announced that they will report Q1, 2013 results After-Market on May 09, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRNM:US $2.19 USD +0.04

VRNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Power Group Corp $0.63 USD -0.005
China Clean Energy Inc $0.05 USD 0.00
Greenshift Corp $0.0025 USD +0.0003
OriginOil Inc $0.43 USD 0.0001
Sino Clean Energy Inc $0.25 USD +0.002
View Industry Companies
 

Industry Analysis

VRNM

Industry Average

Valuation VRNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERENIUM CORP, please visit www.verenium.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.